IFNG and glioblastoma: In a phase Ib randomized trial of DNX-2401 versus DNX-2401 plus interferon gamma (IFN-γ) for recurrent glioblastoma, the overall survival rate at 1 and 1.5 years for all enrolled patients was 33% and 22%, respectively; thus, the use of combinatorial therapy (DNX-2401 + IFN-γ) did not improve patient survival [4].